Youning Zhang, MD
Ophthalmology · San Francisco, CANPI 1881057222
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Alimera Sciences, Inc. at 28.6% of the total. Reporting peaked in 2022 at $3,059 and has fallen 85.8% since, to $436 in 2025.
Across 51 payments — averaging $165.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$2K
- Genentech USA, Inc.$2K
- Eyepoint US, Inc.$1K
- Apellis Pharmaceuticals, Inc.$970
- Alcon$547
- Regeneron Healthcare Solutions, Inc.$512
- plus $1K from 6 others
What the payments were for
- Consulting fees$2,09025%
- Speaking & faculty fees$1,85022%
- Travel & lodging$3234%
- Food & beverage$4,19450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 7 | $2,420 |
| Genentech USA, Inc. | 5 | $1,907 |
| Eyepoint US, Inc. | 5 | $1,036 |
| Apellis Pharmaceuticals, Inc. | 12 | $970 |
| Alcon | 8 | $547 |
| Regeneron Healthcare Solutions, Inc. | 4 | $512 |
| Dutch Ophthalmic, USA | 3 | $336 |
| Bausch & Lomb Americas Inc. | 3 | $285 |
| Biotissue Holdings Inc. | 1 | $204 |
| Neurotech Pharmaceuticals, Inc. | 1 | $110 |
| Genentech, Inc. | 1 | $101 |
| Cardinal Health 108 LLC | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,457 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 67 | $2,365 |
| Cyclosporine | 19 | $1,566 |
| Ketorolac Tromethamine | 30 | $686 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $633 |
| Brimonidine Tartrate | 29 | $601 |
| Atropine Sulfate | 11 | $361 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 19 | $274 |
| Latanoprost | 27 | $242 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Francisco
- Daniel SchwartzSan Francisco$8M
- Gaurav ShahSan Francisco$620K
- Shan LinSan Francisco$374K
- H TanakaSan Francisco$238K
- Jay StewartSan Francisco$219K
- Scott SoSan Francisco$173K
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.